Search

Neervalur V Raghavan

age ~81

from Northbrook, IL

Also known as:
  • Neervalur V Raghauan
  • Nervalur V Raghavan
  • Neervalur V Raghaven
  • Narasimhac Raghavan
  • R Raghavan
  • E Raghavan
  • H Raghavan
  • Raghavan Neervalur
Phone and address:
1258 Walters Ave, Northbrook, IL 60062
847-529-4672

Neervalur Raghavan Phones & Addresses

  • 1258 Walters Ave, Northbrook, IL 60062 • 847-529-4672
  • 2327 Castilian Cir, Northbrook, IL 60062 • 847-498-1706 • 847-498-6986
  • Chicago, IL
  • Long Grove, IL
  • Buffalo Grove, IL
  • Lane, IL

Work

  • Company:
    Rags pharma consulting
    Oct 2012
  • Position:
    President

Education

  • Degree:
    Doctorates, Doctor of Philosophy
  • School / High School:
    University of Southern California
    1967 to 1972
  • Specialities:
    Chemistry

Skills

Pharmaceutical Industry • Validation • Gmp • Medical Devices • Fda • Biotechnology • Parenteral Formulation • Pharmaceutics • Biopharmaceuticals • Regulatory Affairs • Capa • Analytical Chemistry • Chemistry • R&D • Chromatography • Drug Delivery • Drug Development • V&V • Glp • Hplc • Sop • Product Development • Oncology • Technology Transfer • Organic Chemistry • Lifesciences • Process Simulation • Regulatory Requirements • Regulatory Submissions • Formulation • Product Launch • Laboratory • Commercialization • Change Control • 21 Cfr Part 11 • Quality System • Drug Discovery • Clinical Trials • Cro • Ind • Contract Manufacturing • Iso 13485 • Design Control • Clinical Development • Gcp • Aseptic Processing • Immunology • Protein Chemistry • Toxicology • Pharmacology

Industries

Pharmaceuticals
Name / Title
Company / Classification
Phones & Addresses
Neervalur Raghavan
Principal
Vtr Nvr California, LLC
Business Services at Non-Commercial Site
2327 Castilian Cir, Northbrook, IL 60062

Resumes

Neervalur Raghavan Photo 1

President

view source
Location:
Chicago, IL
Industry:
Pharmaceuticals
Work:
Rags Pharma Consulting
President

Baxter International Inc. 2003 - 2010
Vice President, Pharmaceutical Product Development

Baxter International Inc. 1999 - 2002
Senior Director, Pharmaceutical Development

Baxter International Inc. 1996 - 1999
Director, Pharmaceutical Development

Baxter International Inc. 1991 - 1996
Associate Director, New Product Development
Education:
University of Southern California 1967 - 1972
Doctorates, Doctor of Philosophy, Chemistry
Skills:
Pharmaceutical Industry
Validation
Gmp
Medical Devices
Fda
Biotechnology
Parenteral Formulation
Pharmaceutics
Biopharmaceuticals
Regulatory Affairs
Capa
Analytical Chemistry
Chemistry
R&D
Chromatography
Drug Delivery
Drug Development
V&V
Glp
Hplc
Sop
Product Development
Oncology
Technology Transfer
Organic Chemistry
Lifesciences
Process Simulation
Regulatory Requirements
Regulatory Submissions
Formulation
Product Launch
Laboratory
Commercialization
Change Control
21 Cfr Part 11
Quality System
Drug Discovery
Clinical Trials
Cro
Ind
Contract Manufacturing
Iso 13485
Design Control
Clinical Development
Gcp
Aseptic Processing
Immunology
Protein Chemistry
Toxicology
Pharmacology

Us Patents

  • Polymeric Syringe Body And Stopper

    view source
  • US Patent:
    20020139088, Oct 3, 2002
  • Filed:
    Mar 8, 2001
  • Appl. No.:
    09/801864
  • Inventors:
    Archie Woodworth - Barrington IL, US
    John Falzone - Crystal Lake IL, US
    John Darvasi - Hawthorn Wood IL, US
    Amy Gillum - Lake Villa IL, US
    James Kamienski - Chicago IL, US
    Margaret Barnato - Lake Forest IL, US
    Robert Gliniecki - Spring Grove IL, US
    Neervalur Raghavan - Northbrook IL, US
    Craig Sandford - Buffalo Grove IL, US
    Deborah McClelland - Lake Villa IL, US
  • International Classification:
    B65B003/04
    B65B055/04
  • US Classification:
    053/426000, 053/471000
  • Abstract:
    A syringe having a syringe body of a norbornene and ethylene copolymer, the body defining a chamber for containing water and having an opening, a plunger seal of a halobutyl-based elastomer sealing the opening; and wherein the syringe meets all requirements of the United States Pharmocopoeia for sterile water for injection.
  • Premixed Amiodarone Parenteral Solution And Method For Making The Same

    view source
  • US Patent:
    20020143051, Oct 3, 2002
  • Filed:
    Mar 29, 2001
  • Appl. No.:
    09/822767
  • Inventors:
    Mark Doty - Grayslake IL, US
    Christine Rebbeck - Algonquin IL, US
    James Kipp - Wauconda IL, US
    Neervalur Raghavan - Northbrook IL, US
  • International Classification:
    A61K031/343
    A61K031/70
  • US Classification:
    514/469000, 514/023000
  • Abstract:
    A premix parenteral solution for intravenous administration having amiodarone, as an active ingredient, solubilized in a solution of distilled water and about 0.4-12 mg/ml of a non-ionic surfactant to a concentration range of from 0.2 to 6 mg/ml is disclosed. The solution optionally may include an osmotic agent. No dilution of the solution is required before administering to a patient and the sterile packaged solution has an initial pH within the range of from about 2.9 to about 3.2, preferably about 3.1. Additionally, a method for producing an amiodarone solution suitable for intravenous administration is further disclosed.
  • Premixed Amiodarone Parenteral Solution And Method For Making The Same

    view source
  • US Patent:
    7067143, Jun 27, 2006
  • Filed:
    Aug 31, 2001
  • Appl. No.:
    09/945374
  • Inventors:
    Mark J. Doty - Grayslake IL, US
    Christine L. Rebbeck - Algonquin IL, US
    James E. Kipp - Wauconda IL, US
    Neervalur V. Raghavan - Northbrook IL, US
  • Assignee:
    Baxter International, Inc. - Deerfield IL
  • International Classification:
    A61K 9/00
    A61K 9/08
  • US Classification:
    424423, 424426, 424422
  • Abstract:
    A premix parenteral solution for intravenous administration having amiodarone, as an active ingredient, solubilized in a solution of water for injection and about 0. 4-12 mg/ml of a non-ionic surfactant to a concentration range of from 0. 2 to 6 mg/ml is disclosed. The solution optionally may include an osmotic agent. No dilution of the solution is required before administering to a patient and the sterile packaged solution has an initial pH within the range of from about 2. 9 to about 3. 2, preferably about 3. 1. Additionally, a method for producing an amiodarone solution suitable for intravenous administration is further disclosed.

Get Report for Neervalur V Raghavan from Northbrook, IL, age ~81
Control profile